Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Altace · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Ramipril | EXPERIMENTAL | Ramipril 10 mg capsules of Dr. Reddy's Laboratories Limited |
| Altace | ACTIVE_COMPARATOR | Altace@ 10 mg capsules of Kings Pharmaceuticals, USA |
| Name | Type | Description |
|---|---|---|
| Ramipril | DRUG | Ramipril 10 mg Capsules of Dr. Reddy's Laboratories Limited |
| Altace | DRUG | Altace@ 10 mg capsules of Kings Pharmaceuticals, USA |
Inclusion Criteria: 1. Healthy males between 18 and 45 years of age (both inclusive) living in and around Ahmedabad city of western part of India. 2. Having a Body Mass Index (BMI) between 18.5 and 24.9 (both inclusive), calculated as weight in kg/height in m2 3. Not having any significant diseases...
Altace is the brand name for ramipril, a small molecule drug being developed by Dr. Reddy's Laboratories Ltd. It is currently in Phase 1 clinical development, studied in healthy volunteers for bioavailability purposes. Two Phase 1 trials have been completed, with a total enrollment of 108 participants.
Altace is being studied in healthy volunteers to assess the bioavailability of ramipril 10 mg capsules under fasting and non-fasting conditions. These are pharmacokinetic studies, not therapeutic efficacy trials. The drug is in Phase 1 clinical development and is not yet approved for any medical condition.
Altace is developed by Dr. Reddy's Laboratories Ltd, a pharmaceutical company listed on the stock exchange under the ticker RDY. The company is conducting Phase 1 bioavailability studies of ramipril 10 mg capsules in healthy male volunteers in India.
Altace is in Phase 1 clinical development. Two Phase 1 trials have been completed, both focusing on bioavailability of ramipril 10 mg capsules. The drug is investigational and has not been approved by regulatory authorities. No active trials are currently listed.
Altace has two completed Phase 1 trials: NCT01164761, a bioavailability study under fasting conditions, and NCT01164774, a bioavailability study under non-fasting conditions. Both enrolled 54 healthy male volunteers aged 18 years and older in India, with active-controlled design.
Yes, Altace is the brand name for ramipril. The clinical trials for Altace specifically study ramipril 10 mg capsules. Ramipril is the active pharmaceutical ingredient, while Altace is the proprietary name used by the developer.